Guardant Health Nears Buy Point As Sales Outlook Brightens

Guardant Health provides services across the cancer continuum. Shares are near a buy point of 176.58 after a breakout.

Investors Business Daily • Sep 16, 2026

Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 15, 2026

Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the second largest specialty benefits manager in the country spanning more than 23 states. The latest policy update from Shield marks a rapid growth in commercial adopt.

Business Wire • Sep 14, 2026

Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes at the 2026 World Conference on Lung Cancer (WCLC). The conference is hosted by the International Association for the Study of Lung Cancer (IAS.

Business Wire • Sep 9, 2026

Business Insider Names Guardant Health One of America's Most Innovative Businesses

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider's America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category. The inaugural Business Insider list recognizes companies for their innovative performance over the preceding five years, positioning Guardant am.

Business Wire • Sep 8, 2026

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with ESR1 mutations before radiographic progression who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca's next-gener.

Business Wire • Sep 4, 2026

Guardant Health's Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in Carelon Healthcare Services clinical guidelines effective November 15. Carelon Healthcare Services is one of the largest specialty benefits managers in the country and subsidiary of one of the largest health insurance companies in the U.S spanning more than 14 states. The new policy update fr.

Business Wire • Sep 1, 2026

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Benzinga • Sep 1, 2026

U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute

A U.S. court has ordered Guardant Health to pay more than $245.2 million to TwinStrand Biosciences and the University ​of Washington after finding that the company infringed ‌patents covering DNA sequencing technology, TwinStrand said on Monday.

Reuters • Aug 24, 2026

Guardant Health Dives After Losing A Patent Dispute; Judge Orders Royalties

Guardant Health stock tumbled Monday after losing a patent battle against privately held TwinStrand Biosciences.

Investors Business Daily • Aug 24, 2026